Key result
Diabetic platelet reprogramming drives prothrombotic and proinflammatory pathways to accelerate cardiovascular disease.
Why the study?
Emerging evidence suggests platelets contribute to low-grade inflammation and interact with circulating immune cells in diabetes, but these non-traditional thrombo-inflammatory pathways require synthesis to inform future therapeutic targets.
Understanding the thrombo-inflammatory and immunometabolic reprogramming of platelets in diabetes may reveal novel therapeutic targets to reduce cardiovascular risk beyond standard antiplatelet therapy.
May identify novel targets beyond antiplatelet therapy in diabetes; hypothesis-generating and requires prospective validation.
Cardiovascular complications remain the leading cause of morbidity and mortality in individuals with diabetes, driven by interlinked metabolic, inflammatory, and thrombotic changes. Hyperglycaemia, insulin resistance/deficiency, dyslipidaemia, and associated oxidative stress have been linked to abnormal platelet function leading to hyperactivity, and thus increasing vascular thrombotic risk. However, emerging evidence suggests platelets also contribute to low-grade inflammation and additionally possess the ability to interact with circulating immune cells, further driving vascular thrombo-inflammatory pathways. This narrative review highlights the role of platelets in inflammatory and immune processes beyond typical thrombotic effects and the impact these mechanisms have on cardiovascular disease in diabetes. We discuss pathways for platelet-induced inflammation and how platelet reprogramming in diabetes contributes to the high cardiovascular risk that characterises this population. Fully understanding the mechanistic pathways for platelet-induced vascular pathology will allow for the development of more effective management strategies that deal with the causes rather than the consequences of platelet function abnormalities in diabetes.
No takes yet. Share an insight, caveat, or question.
Sagar et al. (2022) conducted a review in Diabetes Mellitus. Platelets in diabetes undergo metabolic and transcriptomic reprogramming that drives both prothrombotic and proinflammatory pathways, contributing to premature and severe cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: